World Journal of Gastroenterology - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 29, Issue 37

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (10465)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-6) series, Tables (1-2) series.

Item

Count

PDF

132

WORD

HTML

7758

Figures (1-6)

410

Tables (1-2)

284

Sum=8625

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

278

Download

488

Sum=766

Publishing Process of This Article

Item

Count

Browse

194

Download

461

Sum=655

Oct 7, 2023 (publication date) through Jan 3, 2025

Times Cited of This Article

Times Cited (15)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Cited by in CrossRef

For:	Zhu K, Kakkar R, Chahal D, Yoshida EM, Hussaini T. Efficacy and safety of semaglutide in non-alcoholic fatty liver disease. World J Gastroenterol 2023; 29(37): 5327-5338 [PMID: 37899788 DOI: 10.3748/wjg.v29.i37.5327]
URL:	https://www.wjgnet.com/1007-9327/full/v29/i37/5327.htm

Number	Citing Articles
1	Antonio Saviano, Natascha Roehlen, Thomas F. Baumert. Tight Junction Proteins as Therapeutic Targets to Treat Liver Fibrosis and Hepatocellular Carcinoma. Seminars in Liver Disease 2024; 44(02): 180 doi: 10.1055/s-0044-1785646
2	Giovanna McGinty, Robert Przemioslo. Effects of excess high-normal alanine aminotransferase levels in relation to new-onset metabolic dysfunction-associated fatty liver disease: Clinical implications. World Journal of Gastroenterology 2024; 30(27): 3264-3267 doi: 10.3748/wjg.v30.i27.3264 Abstract(292) \| Core Tip(254) \| Full Article(HTML)(1281) \| Full Article with Cover (PDF)-1163K(50) \| Audio-772K(5) \| Peer-Review Report-171K(25) \| Answering Reviewers-104K(37) \| Full Article (PDF)-359K(104) \| Full Article (XML)-59K(34) \| Times Cited (1) \| Total Visits (2457) \| Open
3	Rong Ren, Yanxia Pei, Lufei Kong, Yixin Shi. The effect of semaglutide combined with metformin on liver inflammation and pancreatic beta-cell function in patients with type 2 diabetes and non-alcoholic fatty liver disease. Journal of Diabetes and its Complications 2025; 39(2): 108932 doi: 10.1016/j.jdiacomp.2024.108932
4	Mohit Kehar, Samar H. Ibrahim, Charina M. Ramirez, Saista Asif Amin, Tamir Diamond, Saeed Mohammad. Utilization and perspectives of weight loss medications in pediatric metabolic dysfunction‐associated steatotic liver disease. Journal of Pediatric Gastroenterology and Nutrition 2024; 79(3): 661 doi: 10.1002/jpn3.12236
5	Matthew Peverelle, Jonathan Ng, James Peverelle, Ryan D. Hirsch, Adam Testro. Liver decompensation after rapid weight loss from semaglutide in a patient with non-alcoholic steatohepatitis -associated cirrhosis. World Journal of Gastroenterology 2023; 29(47): 6165-6167 doi: 10.3748/wjg.v29.i47.6165 Abstract(405) \| Core Tip(416) \| Full Article(HTML)(3903) \| Full Article with Cover (PDF)-4462K(108) \| Full Article (Word)-227K(26) \| Audio-304K(7) \| Peer-Review Report-234K(43) \| Answering Reviewers-232K(43) \| Full Article (PDF)-656K(159) \| Full Article (XML)-26K(49) \| Times Cited (3) \| Total Visits (6397) \| Open
6	Fabiana Dolovitsch de Oliveira, Samira Mohamad Khalil, Emmily Daiane Buarque de Santana Sato, Matheus Henrique Gonçalves de Souza, Gilmara Coelho Meine. Efficacy and Safety of Fibroblast Growth Factor 21 Analogues for Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Meta-Analysis. Annals of Nutrition and Metabolism 2024; : 1 doi: 10.1159/000541583
7	Hong-Tai Tzeng, Wei-Chia Lee. Impact of Transgenerational Nutrition on Nonalcoholic Fatty Liver Disease Development: Interplay between Gut Microbiota, Epigenetics and Immunity. Nutrients 2024; 16(9): 1388 doi: 10.3390/nu16091388
8	Farah Khaznadar, Omar Khaznadar, Ana Petrovic, Marija Hefer, Fabian Gjoni, Stefan Gjoni, Justinija Steiner, Martina Smolic, Kristina Bojanic. MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development. Current Issues in Molecular Biology 2024; 46(7): 6300 doi: 10.3390/cimb46070376
9	Mohamed Mahmoud Marey, Mohamed Belal, Abdelaziz A. Awad, Eslam Mohammed Rabea, Malak A. Hassan, Ahmed W. Abbas, Abdulqadir J. Nashwan. Efficacy and safety of aldafermin in non-alcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials. Clinics and Research in Hepatology and Gastroenterology 2024; 48(6): 102357 doi: 10.1016/j.clinre.2024.102357
10	Ermina Stratina, Carol Stanciu, Robert Nastasa, Sebastian Zenovia, Remus Stafie, Adrian Rotaru, Tudor Cuciureanu, Cristina Muzica, Catalin Sfarti, Irina Girleanu, Horia Minea, Oana Petrea, Laura Huiban, Stefan Chiriac, Ana-Maria Singeap, Oana Vlad, Camelia Cojocariu, Anca Trifan. New Insights on Using Oral Semaglutide versus Dapagliflozin in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease. Diagnostics 2024; 14(14): 1475 doi: 10.3390/diagnostics14141475
11	Sultan Alfawaz, Abdulhadi Burzangi , Ahmed Esmat. Mechanisms of Non-alcoholic Fatty Liver Disease and Beneficial Effects of Semaglutide: A Review. Cureus 2024; doi: 10.7759/cureus.67080
12	Fatima Ali Raza, Rafiya Altaf, Talha Bashir, Fatima Asghar, Rabiya Altaf, Sohaib Tousif, Aman Goyal, Aisha Mohammed, Mahnoor Faisal Mohammad, Mahfuza Anan, Sajjad Ali. Effect of GLP-1 receptor agonists on weight and cardiovascular outcomes: A review. Medicine 2024; 103(44): e40364 doi: 10.1097/MD.0000000000040364
13	Yue-Hua Yin, Li-Xuan Sang, Bing Chang. Potential therapeutic targets for nonalcoholic fatty liver disease: Glucagon-like peptide 1. World Journal of Gastroenterology 2023; 29(48): 6235-6238 doi: 10.3748/wjg.v29.i48.6235 Abstract(472) \| Core Tip(425) \| Full Article(HTML)(1972) \| Full Article with Cover (PDF)-822K(77) \| Full Article (Word)-106K(30) \| Audio-235K(12) \| Peer-Review Report-231K(50) \| Answering Reviewers-55K(39) \| Full Article (PDF)-349K(159) \| Full Article (XML)-49K(50) \| Times Cited (3) \| Total Visits (4585) \| Open
14	Tereza Dusilová, Jan Kovář, Ivana Laňková, Lenka Thieme, Monika Hubáčková, Petr Šedivý, Dita Pajuelo, Martin Burian, Monika Dezortová, Denisa Miklánková, Hana Malínská, Petra Svobodová Šťastná, Rudolf Poledne, Milan Hájek, Martin Haluzík. Semaglutide Treatment Effects on Liver Fat Content in Obese Subjects with Metabolic-Associated Steatotic Liver Disease (MASLD). Journal of Clinical Medicine 2024; 13(20): 6100 doi: 10.3390/jcm13206100
15	Megan O. Bensignor, Silva Arslanian, Mary Ellen Vajravelu. Semaglutide for management of obesity in adolescents: efficacy, safety, and considerations for clinical practice. Current Opinion in Pediatrics 2024; 36(4): 449 doi: 10.1097/MOP.0000000000001365